HIPAA Rules for Rare Disease Treatment Records: What Providers and Researchers Need to Know

Overview of HIPAA Privacy Rule

The HIPAA Privacy Rule governs how covered entities and their business associates use and disclose Protected Health Information (PHI). In rare disease care, PHI often includes genomic sequencing, novel therapy data, specialized imaging, and longitudinal registry notes that can make individuals easier to identify. That sensitivity elevates the importance of precise privacy controls and disciplined data sharing.

PHI may be used and disclosed without authorization for treatment, payment, and health care operations, and in other specific circumstances permitted by HIPAA. De-Identified Health Information, by contrast, is not PHI and can be used for broader analytics when identifiers are properly removed or an expert determines re-identification risk is very small. Two concepts anchor privacy operations in this context: the Designated Record Set (which defines what patients have the right to access) and the Minimum Necessary Standard (which limits non-treatment uses and disclosures).

• Rare disease implications: small cohorts and distinctive clinical features raise re-identification risk; apply stronger de-identification and cell-size suppression when sharing data.
• Privacy and research interface: the Institutional Review Board waiver pathway and limited data sets enable certain research uses of PHI without authorization, subject to safeguards.
• Lifecycle coverage: the Breach Notification Rule requires specific actions if unsecured PHI is compromised.

Understanding Designated Record Sets

A Designated Record Set (DRS) is the group of records a covered entity uses to make decisions about individuals. Patients have the right to inspect and obtain copies of their records in the DRS. For rare disease programs, mapping your DRS is essential because clinical decision-making often spans clinic notes, advanced diagnostics, and research-informed interpretations.

What typically belongs in the DRS

• Medical records, clinic notes, diagnostic reports (e.g., genetic test interpretations, variant reclassifications returned to care), care plans, and orders.
• Billing records and case or medical management records used to decide on services or benefits.
• Results or analyses—such as reinterpreted variants—that are used, even in part, to make decisions about an individual’s diagnosis or treatment.

What is typically outside the DRS

• Psychotherapy notes and information compiled for legal proceedings.
• Internal quality assurance, peer review files, and administrative working documents not used to make decisions about the individual.
• Research repository files and raw data (e.g., sequencing reads) that are not used for clinical decision-making; once used to inform care, the resulting decision-making content becomes part of the DRS.

Practical tips for rare disease programs

• Document clear criteria for when research-derived insights transition into the medical record.
• Track variant reinterpretations and gene–disease updates; if they affect care, include the updated interpretation in the DRS.
• Keep a DRS inventory so teams know where PHI lives across EHR, lab systems, registries, and secure research platforms connected to care.

Exercising Individual Access Rights

Individuals have a right to timely access to the PHI in the Designated Record Set. You must provide access in the form and format requested if readily producible (for example, a machine-readable electronic copy for genomic reports maintained electronically) and within HIPAA’s required timeframes.

Operational requirements

• Timeliness: fulfill requests without unreasonable delay and no later than 30 calendar days; one 30-day extension is permitted with written notice and reason.
• Form and format: provide electronic copies when you maintain records electronically; avoid unnecessary paper printouts for complex files like variant call summaries if digital delivery is feasible.
• Third-party direction: at the individual’s request, send a copy to a designated third party (e.g., a specialty center or research team) consistent with HIPAA’s rules.
• Fees: limit to reasonable, cost-based fees for labor, supplies, and postage for copies; do not charge for access, retrieval, or verification.
• Identity verification and security: verify requesters without creating barriers; use secure transmission, and warn individuals if they opt for unencrypted channels.

In rare disease care, patients often seek complete genomic reports. Provide the interpretive report and any other decision-making documentation in the DRS; raw research files not used for care are ordinarily outside access scope unless your policies incorporate them.

Applying Minimum Necessary Standard

The Minimum Necessary Standard requires you to limit PHI used, disclosed, or requested to the least amount needed to accomplish the purpose. It does not apply to disclosures for treatment, to the individual, pursuant to a valid authorization, and certain other specified circumstances.

Putting “minimum necessary” into practice

• Role-based access: define access by job role so staff see only what they need (e.g., schedulers view contact and appointment data, not full genomic reports).
• Data segmentation: separate highly sensitive data elements—such as unique phenotypes or rare variant details—when not required for the task.
• Targeted disclosures: for payment and operations, share coded data or summaries rather than full records when possible.
• Limited Data Set: when appropriate for secondary use, provide a Limited Data Set under a Data Use Agreement to remove direct identifiers yet retain useful clinical variables.
• Review routines: periodically audit queries and exports from registries and EHR analytics to confirm minimum necessary is being followed.

Guidelines for Research Use of PHI

HIPAA supports research while protecting privacy. PHI can be used or disclosed for research with an individual’s authorization, or without authorization under specific pathways that manage risk and oversight. Rare disease studies frequently rely on these pathways to enable discovery across small, distributed populations.

Research without individual authorization

• Institutional Review Board waiver: an IRB or Privacy Board may waive authorization when criteria are met (e.g., minimal privacy risk, impracticability without the waiver, adequate safeguards).
• Preparatory to research: investigators may review PHI on-site to design a protocol or assess feasibility but may not remove PHI from the covered entity.
• Research solely on decedents’ information: permitted with documentation that the research is about decedents and PHI is necessary.
• Limited Data Set with Data Use Agreement: share data stripped of direct identifiers for research, public health, or operations under a written agreement.
• De-Identified Health Information: data de-identified via Safe Harbor (removal of specific identifiers) or Expert Determination falls outside HIPAA and can be shared more broadly.

Rare disease safeguards for research

• Elevated re-identification risk: small cohorts, distinctive phenotypes, and unique variant patterns can re-identify individuals even without direct identifiers. Prefer Expert Determination for de-identification and suppress small cells in tables.
• Recruitment boundaries: clinicians may use PHI to identify potential participants under “preparatory to research”; initial contact should follow your IRB-approved plan and HIPAA requirements.
• Return of results: when research results are validated and used for care, capture the clinical interpretation in the DRS and communicate via established clinical channels.

Ensuring Security Rule Compliance

The Security Rule requires administrative, physical, and technical safeguards for electronic PHI (ePHI). Rare disease programs often integrate labs, registries, cloud analytics, and mobile devices, making a comprehensive, risk-based security program essential.

Core security practices

• Risk analysis and management: inventory systems handling ePHI, evaluate threats, and remediate prioritized risks on a defined cadence.
• Access controls: unique user IDs, multi-factor authentication for remote and privileged access, automatic logoff, and least-privilege provisioning.
• Encryption: use strong encryption for ePHI in transit and at rest; apply key management and device-level encryption for endpoints and removable media.
• Audit controls and monitoring: log access and exports from EHRs, labs, and research platforms; review alerts for anomalous queries, mass downloads, or off-hours access.
• Integrity and availability: backup and disaster recovery plans for large genomic files and image archives; test restoration regularly.
• Business associate oversight: execute Business Associate Agreements, verify vendors’ safeguards, and limit PHI sharing to the Minimum Necessary Standard.
• Secure data workflows: segregate research workspaces from clinical systems; restrict cross-environment data movement and require approvals for cohort extractions.

Breach Notification Procedures

A breach is an impermissible use or disclosure of unsecured PHI that compromises privacy or security. Upon discovery, conduct a risk assessment considering the nature and extent of PHI, the unauthorized person who used or received it, whether PHI was actually viewed or acquired, and the extent to which risks were mitigated. If a breach is not excluded or low probability cannot be demonstrated, notifications are required.

Notification timelines and responsibilities

• To individuals: notify without unreasonable delay and no later than 60 calendar days after discovery; include what happened, types of PHI, steps individuals should take, what you are doing, and contact information.
• To HHS: for breaches affecting 500 or more individuals in a state or jurisdiction, notify the Secretary of HHS without unreasonable delay and no later than 60 days; for fewer than 500, log and submit annually within prescribed timelines.
• To media: if 500 or more individuals in a state or jurisdiction are affected, notify prominent media outlets in that area.
• Business associates: must notify the covered entity of breaches, including the identities of affected individuals when known.

Rare disease–specific considerations

• High identifiability: even minimal event details can identify an individual in ultra-rare conditions; craft notices carefully to avoid unnecessary exposure.
• Unsecured vs. secured PHI: encryption that renders PHI unusable, unreadable, or indecipherable can qualify as a safe harbor, reducing notification obligations.
• Post-incident controls: rotate credentials, close exfiltration paths, and revalidate access scopes for research platforms and registries.

Conclusion

For rare disease programs, HIPAA compliance centers on precision: define the Designated Record Set, honor individual access efficiently, enforce the Minimum Necessary Standard, use research pathways appropriately, harden security across all systems, and follow the Breach Notification Rule when incidents occur. These practices protect patients while enabling responsible discovery and care innovation.

FAQs.

What protections does HIPAA provide for rare disease treatment records?

HIPAA protects rare disease records as PHI, limiting uses and disclosures, granting access rights, and requiring safeguards under the Security Rule. If unsecured PHI is compromised, the Breach Notification Rule mandates notifications. For analytics and sharing, De-Identified Health Information or a Limited Data Set can reduce privacy risk while supporting care and research.

How can individuals access their rare disease medical records under HIPAA?

Individuals can request access to the PHI in the Designated Record Set and receive it in the requested form and format if readily producible (including electronic copies of reports). Covered entities must respond within 30 days, may take one 30-day extension with notice, and may charge only reasonable, cost-based copy fees. Individuals can also direct copies to a third party.

When can PHI be used for research without patient authorization?

PHI may be used or disclosed without authorization when an Institutional Review Board waiver is approved, for activities preparatory to research, for research solely on decedents’ information, or by sharing a Limited Data Set under a Data Use Agreement. Data that are properly de-identified fall outside HIPAA and may be used more broadly.

What are the provider responsibilities under the Breach Notification Rule?

Providers must assess potential breaches of unsecured PHI, mitigate harm, and notify affected individuals without unreasonable delay and no later than 60 days. They must also notify HHS (immediately for large breaches; annually for smaller ones) and, if 500 or more individuals in a state or jurisdiction are affected, notify prominent media. Business associate breaches must be reported to the covered entity with available details.